Español
Português
русский
Français
日本語
Deutsch
tiếng Việt
Italiano
Nederlands
ภาษาไทย
Polski
한국어
Svenska
magyar
Malay
বাংলা ভাষার
Dansk
Suomi
हिन्दी
Pilipino
Türkçe
Gaeilge
العربية
Indonesia
Norsk
تمل
český
ελληνικά
український
Javanese
فارسی
தமிழ்
తెలుగు
नेपाली
Burmese
български
ລາວ
Latine
Қазақша
Euskal
Azərbaycan
Slovenský jazyk
Македонски
Lietuvos
Eesti Keel
Română
Slovenski
मराठी
Srpski језик
X
For almost 20 years, we have become the most professional manufacturer in the world, No.1 in China in the methylfolate industry. With strict quality guarantee system, strong brand awareness and high-level after sale service, our company is famous for the business philosophy “Only manufacture and supply premium quality products.”
MTHFR, or methylenetetrahydrofolate reductase, is a crucial enzyme in the metabolism of folate, tasked with converting 5,10-methylenetetrahydrofolate into 6S-5-methyltetrahydrofolate, a form readily absorbed by the human body. In China, a significant portion of the population—78.4%—struggles with MTHFR folate metabolism disorders.
Changsha, China - November 16, 2024 - We are pleased to share that Dr. Lian Zengli, our Chief Scientist, has been elected as a Standing Committee Member of the Nutrition Metabolism and Genetic Disease Prevention and Treatment Special Committee at the inaugural China Women and Children's Health Medical Science and Technology Conference.
Preeclampsia is a hypertensive disorder unique to pregnancy, characterized by high blood pressure and proteinuria. It can lead to severe complications such as premature birth, restricted fetal growth, and placental abruption, posing significant risks to both maternal and fetal health. It is a major cause of maternal mortality worldwide. Recent scientific research has increasingly focused on the relationship between biomarkers like folate, homocysteine (HCY), and vitamin B12, and the risk of preeclampsia.
Preeclampsia, a condition unique to pregnancy, affects 5-10% of expecting mothers and is a significant threat to both maternal and fetal health, being a leading cause of maternal and perinatal mortality. Recent studies have revealed a strong correlation between homocysteine (HCY) levels in early pregnancy and the risk of developing preeclampsia.
Preeclampsia, a complex disorder unique to pregnancy, is characterized by high blood pressure and proteinuria, typically emerging after the 20th week of gestation. It poses significant risks to both the mother and the fetus. While the exact etiology remains elusive, it is believed to involve genetic, immunological, and endothelial dysfunction factors.
Preeclampsia, a stealthy threat during pregnancy, has long been a source of concern for countless families. It poses a risk to both maternal health and fetal development. In the quest for effective preventative measures, the medical community has made significant strides with a recent discovery—5-Methyltetrahydrofolate (5-MTHF).
Copyright © 2021 Lianyungang Jinkang Hexin Pharmaceutical Co.,Ltd. All Rights Reserved jinkang-chem
Online Service